Current Issues and Future Directions of Oncolytic Adenoviruses
Open Access
- 1 February 2010
- journal article
- review article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (2), 243-250
- https://doi.org/10.1038/mt.2009.266
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster ModelMolecular Therapy, 2009
- Virus Binding to a Plasma Membrane Receptor Triggers Interleukin-1α-Mediated Proinflammatory Macrophage Response In VivoImmunity, 2009
- Oncolytic Viruses: Time to Compare, Contrast, and Combine?Molecular Therapy, 2009
- INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studiesCancer Gene Therapy, 2009
- An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vectorCancer Gene Therapy, 2009
- Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivoProceedings of the National Academy of Sciences, 2008
- E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor modelsCancer Gene Therapy, 2007
- Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAILCancer Gene Therapy, 2007
- Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational controlBreast Cancer Research and Treatment, 2007
- Core labeling of adenovirus with EGFPVirology, 2006